02 May 2017
By Dr Wendy Winnall - PCFA Research Team
Immunotherapy for cancer is an exciting breakthrough that is dramatically improving treatment options. There are promising trials underway for prostate cancer immunotherapies such as therapeutic vaccines and checkpoint blockade inhibitors. An effective immunotherapy for blood cancers, called CAR-T cells, has not seen the same success for prostate cancer. But recent results presented at the 2017 AACR conference show for the first time that CAR-T cells can work well for prostate cancer. These results pave the way for the first clinical trial of this treatment in prostate cancer patients.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
